Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight [Yahoo! Finance]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Yahoo! Finance
Additionally, emerging candidates such as LX2020 and LX2006 from Lexeo Therapeutics and AB-1002 from AskBio exemplify targeted, mechanism-driven strategies aimed at correcting or compensating for underlying genetic defects in hypertrophic cardiomyopathy, dilated cardiomyopathy, and restrictive cardiomyopathy. LAS VEGAS Dec. 15, 2025 /PRNewswire/ -- DelveInsight's Gene Therapies for Cardiomyopathies Market Insights report includes a comprehensive understanding of current treatment practices, emerging gene therapies for cardiomyopathies, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). Gene Therapies for Cardiomyopathies Market Summary The market size for gene therapies for cardiomyopathies in the leading markets is expected to grow significantly by 2034. The United States accounted for the highest gene therapies for cardiomyopathies treatment market size in 7MM in 2024, i
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..MarketBeat
- Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript [Seeking Alpha]Seeking Alpha
- Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) ForumGlobeNewswire
- Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.MarketBeat
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 12/8/25 - Form SCHEDULE
- 11/28/25 - Form EFFECT
- 11/26/25 - Form 424B3
- LXEO's page on the SEC website